Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $7.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target cut by stock analysts at HC Wainwright from $8.00 to $7.00 in a report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $0.87 on Friday. The company has a market cap of $108.12 million, a P/E ratio of -0.68 and a beta of 0.25. Karyopharm Therapeutics has a 1 year low of $0.62 and a 1 year high of $1.95. The firm has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.10.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $33.13 million for the quarter, compared to analysts’ expectations of $35.02 million. As a group, equities research analysts expect that Karyopharm Therapeutics will post -1.25 EPS for the current year.

Insider Activity at Karyopharm Therapeutics

In other Karyopharm Therapeutics news, Director Deepika Pakianathan sold 360,744 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $1.00, for a total value of $360,744.00. Following the completion of the sale, the director now directly owns 11,209 shares in the company, valued at $11,209. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 1,282,902 shares of company stock valued at $1,244,993 over the last ninety days. 4.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bleakley Financial Group LLC acquired a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $33,000. Simplicity Solutions LLC acquired a new position in Karyopharm Therapeutics during the fourth quarter valued at $33,000. SG Americas Securities LLC lifted its position in Karyopharm Therapeutics by 295.0% during the fourth quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock valued at $64,000 after purchasing an additional 54,839 shares during the period. Simplicity Wealth LLC acquired a new position in Karyopharm Therapeutics during the first quarter valued at $66,000. Finally, Exchange Traded Concepts LLC lifted its position in Karyopharm Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 115,864 shares of the company’s stock valued at $100,000 after purchasing an additional 29,380 shares during the period. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).